GeneNews' Innovative Diagnostic Laboratory Appoints David Byram Chief Commercial Officer
TORONTO, July 12, 2018 /CNW/ - GeneNews Limited ("GeneNews" or the "Company") (TSX:GEN) today announced the appointment of David Byram as the Chief Commercial Officer for its U.S. Lab, Innovative Diagnostic Laboratory, LLP ("IDL"). Mr. Byram will oversee all IDL's customer-facing activities including sales, client relations and commercial operations.
Mr. Byram is a senior commercial executive with over 25 years of pharmaceutical, biotechnology and medical device industry leadership experience. He has built successful product launches across multiple therapeutic areas that incorporate innovative sales and marketing strategies which have driven wide market adoption and revenue generation. Mr. Byram has broad health category experience including oncology/hematology, gastroenterology, rheumatology, neurology, cardiology and urology. During his career, Mr. Byram has overseen all commercial operations including sales and marketing, market access and pricing, channel strategy and new product development. Prior to joining IDL, Mr. Byram was the Vice President, Commercial & Government Affairs for Braeburn Pharmaceuticals. Prior to Braeburn, he held positions as SVP, Commercial Affairs for Orexo AB/US, US Director, Public Sector for Indivior plc, and Sr. Director, Strategic Accounts and Public Affairs for Janssen Biotech, a division of Johnson & Johnson. David is highly focused on delivering healthcare outcomes which create value for patients, physicians, payers and investors.
"We are extremely pleased to have David join IDL's senior leadership team," commented James R Howard-Tripp, Chairman and CEO of GeneNews. "With a very experienced executive to energetically manage the company's commercial operations and sales strategy, we can increase the pace of meeting our targeted sales objectives for 2018."
"It is an exciting time to be in the liquid biopsy space and I look forward to utilizing my commercialization expertise as well as prior sales experience in oncology and gastroenterology to support IDL's efforts to achieve our growth objectives and ensure the highest satisfaction of our clients," said Mr. Byram.
About GeneNews
GeneNews, an innovator in the liquid biopsy space, is committed to becoming a leader in advanced diagnostics and personalized medicine, serving as a strong commercialization outlet for early detection of cancer and other chronic diseases. Our mission is to identify, assess and make commercially available a comprehensive menu of diagnostics that provide physicians and patients with personalized clinical intelligence and actionable information to improve health outcomes through the early diagnosis of disease.
Our Richmond, Virginia-based Innovative Diagnostic Laboratory clinical reference lab specializes in traditional and advanced clinical evidence-based blood testing that helps find, understand, and address cancer risk in patient populations. Currently, IDL offers risk assessment blood tests for four prevalent cancer types - colon, lung, prostate and breast. GeneNews' common shares trade on the Toronto Stock Exchange under the symbol 'GEN'. More information on GeneNews and IDL can be found at www.GeneNews.com and www.myinnovativelab.com, respectively.
Forward-Looking Statements
This press release contains forward-looking statements identified by words such as "expects", "will", "may" and similar expressions, which reflect the Company's current expectations regarding future events, including with respect to the receipt of shareholder approval. The forward-looking statements involve risks and uncertainties that could cause actual events to differ materially from those projected herein including the state of the equity capital markets, the receipt of required approvals, the future financial and operating performance of the Company and its subsidiaries, requirements for and availability of additional capital and the general business and political environment including in the healthcare sector. Investors should consult the Company's ongoing quarterly filings and annual reports for additional information on risks and uncertainties relating to these forward-looking statements. The reader is cautioned not to rely on these forward-looking statements. The Company disclaims any obligation to update these forward-looking statements, except as required by law.
SOURCE GeneNews Limited
Health Canada Approves Tagrisso® (osimertinib) as First-line Treatment for EGFR-Mutated Non-Small Cell Lung Cancer
Pivotal FLAURA study demonstrated 18.9 months median progression-free survival for patients receiving Tagrisso versus 10.2 months compared with earlier generation EGFR tyrosine kinase inhibitors
MISSISSAUGA, ON, July 12, 2018 /CNW/ - AstraZeneca Canada today announced that Health Canada has approved Tagrisso® (osimertinib) for the first-line treatment of patients with locally advanced (not amenable to curative therapies), or metastatic non-small cell lung cancer (NSCLC) whose tumours have epidermal growth receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations (either alone or in combination with other EGFR mutations). Tagrisso has been granted a Notice of Compliance under Priority Review status based on data from the phase III FLAURA trial, which showed that patients who received first-line treatment of Tagrisso demonstrated 18.9 months median progression-free survival (PFS) versus 10.2 months in patients receiving earlier generation first-line EGFR tyrosine kinase inhibitors (TKI) erlotinib or gefitinib.i In addition, preliminary overall survival (OS) data from the study indicated a 37 per cent reduction in the risk of death (Hazard Ratio [HR] 0.63 at 25% maturity, not statistically significant as the OS data is still immature).ii
Until now, Tagrisso was approved as the only second-line treatment for patients with EGFR mutated NSCLC that progressed on EGFR-TKI treatment and whose tumour tested positive for the EGFR T790M mutation, the most common mutation acquired by resistance to TKI therapy.
For many patients with advanced EGFR mutated NSCLC, their first treatment is their only treatment. Today's announcement means that many more patients are now eligible to be treated earlier in their treatment journey with Tagrisso, a medicine that has been proven in a clinical study to provide almost nine months PFS benefits beyond that of earlier generation first-line EGFR TKI therapies.
More than half of all patients with EGFR mutated NSCLC will see the cancer spread to the central nervous system (CNS), including the brain, over the course of their disease. The development of CNS metastases leads to a poor prognosis and has a negative impact on quality of life. The FLAURA trial data demonstrated that PFS results for patients treated with first-line Tagrisso were consistent across all patient subgroups, including patients with or without CNS metastases. The FLAURA trial was the first and only study to demonstrate this level of efficacy in this difficult-to-treat patient population.iii
"The approval of Tagrisso in this first-line setting represents a major advancement in the treatment of EGFR mutated lung cancer," said Dr. Glenwood Goss, Professor of Medicine, University of Ottawa, and Director of Clinical and Translational Research at the Ottawa Hospital Cancer Centre. "As an oncologist, I believe in using the best treatment first, and Tagrisso has shown to significantly extend progression-free survival and improve treatment of central nervous system metastases as a first-treatment of EGFR mutation positive non-small cell lung cancer. I am pleased to be able to offer this life-altering treatment as a first-line option to patients who need it."
The Health Canada approval of Tagrisso is based on the results of the phase III FLAURA trial. The trial assessed the efficacy and safety of Tagrisso 80mg once daily compared to earlier generation first-line EGFR-TKIs in previously untreated patients with locally advanced or metastatic EGFR mutated NSCLC.iv The trial was double-blinded and randomized, with 556 patients across 29 countries and demonstrated a statistically significant and clinically meaningful median PFS, 18.9 months for Tagrisso vs. 10.2 months for comparator (HR 0.46; 95% confidence interval [CI] 0.37, 0.57; p<0.001).v
Safety data for Tagrisso were in line with those observed in prior clinical trials.vi The treatment was well tolerated, with grade 3 or higher adverse events (AEs) occurring in 34 per cent of patients taking Tagrisso vs 45 per cent in the comparator arm.vii The most common adverse reactions (≥20%) in patients treated with Tagrisso were diarrhea (58%), rash or acne (58%), dry skin (36%), paronychia (35%), decreased appetite (20%) and stomatitis (29%).viii
Detailed results from the FLAURA trial are published online in the New England Journal of Medicine.ix
"The approval of Tagrisso as a first-line treatment is welcome news for lung cancer patients, for whom every day counts," said Shem Singh, Executive Director of Lung Cancer Canada. "Innovation in treatment offers hope against this difficult-to-treat disease and gives patients and their families a chance to spend more quality time together. This Health Canada approval is an important first step, and we call on all stakeholders to work together to ensure that Tagrisso in the first-line setting is publicly funded for all that need it."
About Non-Small Cell Lung Cancer (NSCLC)
Lung cancer is the most commonly diagnosed cancer in Canada (excluding non-melanoma skin cancers), and the leading cause of death from cancer in Canada for both men and women.x On average, 78 Canadians are diagnosed with lung cancer every day and 58 Canadians will die from lung cancer each day.xi Lung cancer is a diverse disease which is often diagnosed at a late stage, making it difficult to treat.
There are two major types of lung cancer, non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC), which are determined by the type of cell in which the cancer starts.xii Non-small cell lung cancer is the most common form of lung cancer and accounts for 85 to 90 per cent of all lung cancers in Canada.xiii Often diagnosed in late stage, fewer than 17 per cent of patients with NSCLC will live more than five years following diagnosis.xiv Half of NSCLC cases are associated with known mutations.xv EGFR mutation occurs in approximately 10-35 per cent of NSCLC cases.xvi Most patients with EGFR mutated NSCLC progress following first-line treatment with approved TKIs within 9-12 months, due to acquired mutation resistance, of which the most common is EGFR T790M.xvii
About Tagrisso
Tagrisso (osimertinib) is a third-generation, irreversible EGFR-TKI designed to inhibit both EGFR-sensitising and EGFR T790M-resistance mutations, with clinical activity against CNS metastases. Tagrisso 40mg and 80mg once-daily oral tablets have been approved in Canada, the US, EU, Brazil and Russia for first-line EGFR mutated advanced NSCLC, and in more than 75 countries including Canada, the US, EU, Japan and China for patients in the second-line with EGFR T790M mutation-positive advanced NSCLC. Tagrisso is also being investigated in the adjuvant setting and in combination with other treatments.
Tagrisso was first approved with conditions by Health Canada (NOC/c) in July 2016 as the first and only medicine indicated for patients with locally advanced or metastatic EGFR T790M mutation-positive NSCLC. This was followed by a full approval as a second-line treatment in January 2018, based on the phase III AURA3 trial that demonstrated significant improvement in PFS with Tagrisso compared to chemotherapy.
In May 2017, Tagrisso in the second-line setting received a positive clinical recommendation for reimbursement by the pan-Canadian Oncology Drug Review (pCODR).
AstraZeneca is committed to working with the pan-Canadian Pharmaceutical Alliance (pCPA), provinces and territories to ensure that Tagrisso is made publicly available as soon as possible for appropriate patients in both the first and second-line settings. For patients, there is no time to wait.
About AstraZeneca
AstraZeneca is a global, innovation-driven biopharmaceutical business with a primary focus on the discovery, development and commercialization of primary and specialty care medicines that transform lives. Our primary focus is on three important areas of healthcare: Cardiovascular and Metabolic disease; Oncology; and Respiratory, Inflammation and Autoimmunity. AstraZeneca operates in more than 100 countries and its innovative medicines are used by millions of patients worldwide. In Canada, we employ more than 675 employees across the country and our AstraZeneca Canada headquarters are located in Mississauga, Ontario. For more information, please visit the company's website at www.astrazeneca.ca.
| References |
| _________________________________ |
| i |
AstraZeneca Canada Inc., Tagrisso® (osimertinib), Product Monograph. July 2018. |
| ii |
Ibid. |
| iii |
Soria J-C, et al. Osimertinib in Untreated EGFR-Mutated Advanced Non–Small-Cell Lung Cancer. N Engl J Med. 2018;378:113-125 |
| iv |
Ibid. |
| v |
Ibid. |
| vi |
Ibid. |
| vii |
Ibid. |
| viii |
Soria J-C, et al. Osimertinib in Untreated EGFR-Mutated Advanced Non–Small-Cell Lung Cancer. N Engl J Med. 2018;378:113-125 |
| ix |
Ibid. |
| x |
Canadian Cancer Society. Lung Cancer Statistics. Accessed July 6, 2018. Available at: http://www.cancer.ca/en/cancer-information/cancer-type/lung/statistics/?region=pe |
| xi |
Lung Cancer Canada, The Faces of Lung Cancer Report 2017. Accessed January 26, 2018. Available at: http://www.lungcancercanada.ca/LungCancerCanada/media/Documents/Faces-of-Lung-Cancer-Report-2017.pdf |
| xii |
Ibid. |
| xiii |
Molina JR, et al. Non-small cell lung cancer: Epidemiology, risk factors, treatment and survivorship. Mayo Clin Proc. 2008 May; 83(5): 584-594. |
| xiv |
Lung Cancer Canada, The Faces of Lung Cancer Report 2017. Accessed January 26, 2018. Available at: http://www.lungcancercanada.ca/LungCancerCanada/media/Documents/Faces-of-Lung-Cancer-Report-2017.pdf |
| xv |
Savas P, Hughes B, Solomon B. Targeted therapy in lung cancer: IPASS and beyond, keeping abreast of the explosion of targeted therapies for lung cancer. J Thorac Dis. Oct 2013;5 Suppl 5:S579-592. |
| xvi |
Dong, Lijun, Dan Lei, and Haijun Zhang. "Clinical Strategies for Acquired Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Resistance in Non-Small-Cell Lung Cancer Patients." Oncotarget 8.38 (2017): 64600–64606. PMC. Accessed on June 20, 2018. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5610029/ |
| xvii |
Mazza, Valentina, and Federico Cappuzzo. "Treating EGFR Mutation Resistance in Non-Small Cell Lung Cancer – Role of Osimertinib." The Application of Clinical Genetics 10 (2017): 49–56. PMC. Accessed on June 20, 2018. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5536882/ |
SOURCE AstraZeneca
 |
MedReleaf to Sponsor Cancer Trial in Collaboration with the Ontario Clinical Oncology Group
In affiliation with Hamilton Health Sciences and the Department of Oncology at McMaster University
MARKHAM, ON, July 12, 2018 /CNW/ - MedReleaf Corp. (TSX:LEAF) ("MedReleaf" or the "Company"), in collaboration with the Ontario Clinical Oncology Group ("OCOG") today announced it will sponsor a cancer trial to improve the management of cancer pain using medical grade cannabis oil.
The OCOG directed by Dr. Mark Levine will coordinate the trial. Dr. Marissa Slaven, a specialist in pain management and palliative care is the Principal Investigator. The study will be conducted at the HHS Juravinski Cancer Centre in Hamilton over a one-two year period. Patients with cancer related pain will be administered MedReleaf's uniquely formatted cannabis oil capsules with the objective of improving pain management.
Cancer patients experiencing pain despite other pain medications may be eligible to participate. The aim of the trial is to assess the effect of cannabis oil in relieving their symptoms and to gain information on the best oral dosing regimen. Patients will receive an oil combining THC and CBD.
"Patients with cancer often suffer from significant pain and we know that while managing the pain with narcotics is often necessary, it is also fraught with issues," said Dr. Marissa Slaven. "Anecdotally, cancer patients have been telling us that cannabis products help their pain. Thanks to MedReleaf's commitment to advancing medical science we will now be able to start gathering the data needed to help our patients live better."
"Collaborating with the Ontario Oncology Group under the direction of Dr. Levine and its affiliates speaks to MedReleaf's foundation as an R&D driven company," said Neil Closner, CEO MedReleaf. "We are thrilled to have the opportunity to be involved in this important cancer trial which has the potential to positively impact the lives of cancer patients while advancing our understanding of the therapeutic benefits of medical cannabis and validating new treatment options for patients."
About OCOG
OCOG is an academic trials group based in the Escarpment Cancer Research Institute, a joint research institute of Hamilton Health Sciences and McMaster University. OCOG works with networks of investigators to design and conduct cancer clinical trials provincially, nationally, and beyond. OCOG was established in 1982 and since then over 12,000 patients have been entered in OCOG studies. The results of which have impacted on clinical care.
For more information on this and other cancer clinical trials, please visit www.ocog.ca
About MedReleaf Corp.
Canada's most awarded licensed producer, MedReleaf is an R&D-driven company dedicated to innovation, operational excellence and the production of industry leading, top-quality cannabis. Sourced from around the world and carefully cultivated in one of two state-of-the-art ICH-GMP and ISO 9001 certified facilities in Ontario, with a third facility currently in development, a full range of premium MedReleaf products are delivered to the global medical market. We serve the therapeutic needs of patients seeking safe, consistent and effective medical cannabis and provide a compelling product offering for the adult-use recreational market.
For more information on MedReleaf, its products, research and how the company is helping patients #livefree, please visit www.medreleaf.com or follow @medreleaf
SOURCE MedReleaf Corp.
Jersey Shore's Vinny Guadagnino joins
star-studded talent lineup at
25th annual canfitpro World Fitness Expo
Media accreditation still open for the world’s largest fitness education event at the Metro Toronto Convention Centre August 8-12
TORONTO, ON — canfitpro announced today MTV reality star Vinny Guadagnino will join headliners Derek Hough of World of Dance and celebrity trainer, Jillian Michaels, at the 2018 World Fitness Expo this August. Fitness enthusiasts and industry professionals alike will get a chance to preview the latest trends at the world’s largest fitness conference and trade show. Now in its milestone 25th year, the Expo returns to the Metro Toronto Convention Centre from August 8-12 to entertain thousands with world-renowned workouts and education seminars.
Vinny Guadagnino
Rising to fame on the MTV hit reality series Jersey Shore, which ran for six seasons from 2009-2012 and is the highest rated series in MTV’s history, Vinny now stars in its reboot series, Jersey Shore Family Vacation. In addition to reality TV stardom, he is a New York Times bestselling author, actor and activist. At World Fitness Expo, Vinny will be taking part in a Q&A and Meet & Greet, sharing his story of fitness, nutrition and overcoming social anxiety.
Additional notable talent joining the event this year include:
- Billy Blanks – Creator of the revolutionary Tae Bo Fitness® workout
- Derek Hough – Star of NBC’s World of Dance
- Jillian Michaels – Reality TV star and creator of BODYSHRED™
- The Brutez – The dancing bodybuilders with an electrifying and intensely effective style
- Thomas Delauer – One of the world’s leading experts on the keto diet and intermittent fasting
- Tosca Reno – Bestselling author of the Eat-Clean diet
- Vikram Vij – Restaurateur, cookbook author and former Dragon’s Den judge
Attendees can choose from a variety of educational sessions presented by industry experts and workouts lead by the world’s top fitness superstars. For additional activities, contests and exhibitor prizes, guests can visit Expo Hall, open August 10 and 11. General admission tickets to Expo Hall can be purchased online for $17.70.
Media can apply for accreditation at worldfitnessexpo.com/media-credentials.
Website: www.worldfitnessexpo.com
Twitter: @canfitpro
Instagram: @canfitpro
Facebook: @canfitpro
Hashtag: #canfitpro #worldfitnessexpo
About canfitpro
canfitpro is the largest provider of education in the Canadian fitness industry. Founded in 1993, canfitpro delivers accessible, quality education, certifications, events and membership services. canfitpro's over 24,000 members include some of the world's finest fitness professionals, health club operators, industry suppliers, and fitness consumers.
WHAT: Yesterday evening, SPINCO surprised guests at their 4th birthday party with a performance by Loud Luxury at REBEL. The Canadian DJ duo set the tone for SPINCO's largest ride ever, providing upbeat music including their popular single, 'Body'.
WHEN: Wednesday, July 11, 2018
WHERE: REBEL (11 Polson Street)
PHOTO LINK: http://bit.ly/2upK2EF
PHOTOGRAPHER: Arthur Mola
VIDEO LINK: http://bit.ly/2mb2xZN
HANDLES: @SPINCOToronto | #TeamSPINCO | #SPINCOTurns4
NOTES: SPINCO hosted a 100+ person spin class in support of Right To Play as a special thank you to their community of riders and supporters for an amazing four years.
LELO summer tips : Challenge accepted: Surviving Summer Festival Season
Hello,
You got the tickets ages ago, finally settled on the perfect outfit, prepped your selfie stick and so the only thing left is to show up and slay the summer festival scene. But as most of you already know - that's easier said than done.
It's the same tired old story every year - you planned everything down to the most minute detail and counted down the days until you could finally stand in front of your favorite band. You couldn't wait to blow off some steam and dance your heart out until the break of dawn, but
But. But something came up again - it started raining, you got separated from your friends, of course, the cell-reception is poor, you look like you rolled around in a giant beer puddle
You know, the usual.
The secret to having a good time at any festival, unencumbered by worries such as I stink like a wet dog or I will die of thirst right this second or Is this condom still okay even though I had it for 5 years? rests in detailed planning. By using a couple of more grey cells than usual, you'll successfully avoid dealing with crisis upon crisis and manage to enjoy yourself to the fullest. Yes, it makes the whole thing a whole lot less spontaneous, but it's totally worth it.
In order to save you some time and because we've all been there, here is some useful advice that will get you on the right track to the best time of your life:
1. Play by the rules.
Yes, it's very chic to be a rebel, but having to throw away that expensive perfume bottle you spent waaay too much on because you can't have it on festival grounds definitely does not fall under the chic category. It's just dumb. And very sad. Every festival website has the list of items that aren't allowed on the grounds. Read it and pack accordingly. Also, make sure to hit that ATM. Most places have a one-time-entrance-only policy which means you'll be stranded and at the mercy of festival economy with no money.
2. Water definitely isn't the life of the party, but without it, you won't be either.
You won't be able to get your water bottle past the security guards, so as soon as you enter, make a beeline for the first bar and get a couple of waters. Stuff them in your trusty festival backpack (a must-have), then happily order your spirit of choice. Water will save you from the merciless summer heat, and if you drink enough of it, it might even spare you from a raging hangover the following morning.
3. Pack smart and dress in layers.
Luckily, boho is always in during festival season. Make sure your outfit consists of several practical pieces that will see you through all weather conditions - rain, shine or beer spray from overzealous partiers. Focus on natural fabrics that will let your skin breathe freely (no more Eau De Wet Dog) and bring a spare shirt and a spare pair of socks. Throw away that decade-old condom and get a new one. This might be the year you finally get lucky.
4. Go analog with your meetup plans.
Think back to any concert you've been to in the past. It got pretty loud, didn't it? To avoid excess wandering and frustrating attempts to make a phone call while waving your hands in the air like an idiot who didn't care to make proper contingency plans, set up a meetup spot in case you get separated from your friends. Try to be as precise as possible. Meet me by the beer stand isn't precise when there are 20 of them lying around.
5. Wet-wipes are more than baby bum cleaners.
You'll thank us after your first encounter with the toilet. Plus they're handy at getting that cheap beer smell out of your skin.
6. Stay safe and play safe.
Yes, we know it's summer and you just want to lie back and enjoy yourself. The outside world kind of fades away the moment you step onto the festival grounds and every single one of us turns into a glutton for the good times. LELO, the world's leading pleasure brand and a big advocate of the good times, wants you to make an effort and enjoy yourself responsibly. That kind of sounds like a big fat oxymoron but it makes perfect sense, just let us explain. It's really hard not to let go and enjoy the moment once the rhythm sets in. You're ready to give in and let yourself get carried away by the pulsating lights and undulating bodies and trust that all seems right with the world. Consequences? Adulthood? Responsibilities? Pish, it's summer! Remember those shiny new condoms you bought? If you treated yourself with LELO HEX condoms, it'll only take a second to slip one on, let go and completely forget that it's there. Responsible enjoyment? Doesn't seem like a longshot after all.
TimiCoin/TimiHealth Announces TimiDNA to Empower Individuals to Secure and Control Their Personal DNA Fingerprint
NEWS PROVIDED BY
TimiCoin/TimiHealth
AUSTIN, Texas, July 11, 2018 /PRNewswire/ -- TimiCoin/TimiHealth (www.TimiCoin.io) today announced a breakthrough strategy in blockchain technology called TimiDNA which will empower individuals to secure and control how their personal DNA data is used.
TimiDNA's thoughtfully engineered technology is designed to achieve three important goals:
1. Individuals who already have DNA results through another source can access easy-to-use tools within TimiPatient to download and securely store those results;
2. Those who have never taken a DNA test can establish complete control of their own DNA data through TimiDNA services. TimiDNA will provide consumers with a simple swab test kit and their DNA information will be securely stored;
3. Once an individual's data is in the TimiPatient app, he/she will own it, control it, and have the ability to utilize it as an asset which can be monetized.
"TimiDNA offers a superior option to using any of today's current genetic testing services that have proliferated in the marketplace, and that monetize your data without a patient's understanding or participation in revenues. It is a more effective way to store your genetic information on a purposefully driven and secure blockchain system," said TimiHealth's clinical advisor, Dr. Jim Bonnette.
"In this way, an individual can decide who sees, and more importantly, who uses their DNA results and for what purpose. If you want, you can decide to license your results for research while retaining rights to your own DNA. Given that DNA testing will become progressively more ubiquitous in healthcare, it's imperative that people are given the opportunity to control their own DNA data."
TimiDNA offers individuals unprecedented privacy and control over their DNA data.
"It can be very surprising to individuals when they learn the genetic testing they've done, or even lab results from biopsies, etc. are widely shared with third parties," said Will Lowe, founder of TimiCoin/TimiHealth.
"This very personal data should in fact be owned by the very person from whom the DNA was harvested," he added.
"TimiHealth's mission is to turn an individual's very personal health data back over to each individual who will then own and control it. It's the perfect moment in history where the technology can truly support the governmental and consumer outcry for individuals to own their own data. The California Consumer Privacy Act of 2018 is an example of where the future of the ownership of data is going, and individual control and transparency is exactly what TimiHealth is aligned with," said Joyce Lignell, Chairwoman of TimiHealth's Advisory Board.
Media Contact: Adrienne Mazzone amazzone@transmediagroup.com 561-750-9800 x2270
SOURCE TimiCoin/TimiHealth
Related Links
https://www.timicoin.io/
CROP JV Partner 'XHemplar Italia' Plants 25 Acres of High CBD, Low THC 'Cannabis Light'
VANCOUVER, July 11, 2018 /CNW/ - CROP Infrastructure Corp. (CSE: CROP) (OTC: CRXPF) ("CROP" or the "Company") announces its 30% owned Italy Joint Venture partner 'XHemplar Italia' has planted 25 acres or 1,089,000 square feet of high CBD 'Cannabis Light' in North Eastern Italy. This represents over a 100% increase on the previously announced capacity announced in press release dated June 27th 2018.
The Joint Venture's resulting high CBD "Cannabis Light" will be processed and sold into international CBD markets under white label, the venture's house name XHemplar and Crop brands Tiffany CBD and Hempire Italia. The company will also use the production to infuse its recently announced therapeutic and cosmetic product lines, licensed from The Yield Growth Corp., which transaction is now complete giving Crop exclusive rights in Italy to over 55 wellness products.
According to Arcview Market Research and its partner, BDS Analytics, government-subsidized healthcare spending (worldwide market at $1.3-trillion) is expected to make Europe among the fastest growing and largest medical cannabis markets in the world. Arcview expects Italy to be the second largest cannabis market in Europe by 2027 with $1.2 billion in sales.
CROP Infrastructure Director & CEO Michael Yorke states: "The company is extremely encouraged by the fast pace with which the team at XHemplar has commenced production in Italy. CROPs portfolio of cannabis infrastructure assets now includes cultivation properties in California, Washington State, Nevada, Italy and joint ventures on West Hollywood and San Bernardino dispensary applications. CROP has developed a portfolio of 15 Cannabis brands and also has US and Italian distribution rights to a line of over 55 cannabis topical products. Management will continue to aggressively pursue new world-wide opportunities and expand its portfolio of tenant growers and infrastructure assets in strategic licensed jurisdictions."
XHemplar Chairman and CROP Infrastructure VP of M&A, EMEA Andrea Castiglione states: "This is a great start for the company in Italy. We are pleased by how quickly our joint venture team has worked together to begin this initial production."
About XHemplar
XHemplar is a joint venture between CROP Infrastructure Stratto, LLC and the AnCaPa SRL of the prominent Castiglione family. This endeavor will be led locally by the CEO of XHemplar Giuseppe Castiglione who has spent the past 30 years in National and International politics roles ranging from Vice President of Sicily - with special delegation on Agriculture and Industrial development - to member of the European Parliament - where he acted as head supervisor of the European Wine Reform - to Vice Minister of Agriculture and Forestry Politics for the Italian central government in three consecutive legislatures. As an agricultural company XHemplar enjoys substantially lower tax rates with 4% VAT in Italy from which the company will greatly benefit in these early stages.
About CROP
Crop Infrastructure Corp. is publicly listed on the Canadian Securities Exchange and trades under the symbol "CROP" and in the US under the symbol "CRXPF". CROP is primarily engaged in the business of investing, constructing, owning and leasing greenhouse projects as part of the provision of turnkey real estate solutions for lease-to-licensed cannabis producers and processors offering best-in-class operations. The Company's portfolio of projects includes cultivation properties in California and Washington State, Nevada, Italy and a joint venture on West Hollywood and San Bernardino dispensary applications. CROP has developed a portfolio of 15 Cannabis brands and also has US and Italian distribution rights to a line of over 55 cannabis topical products from The Yield Growth Corp.
Disclaimer for Forward-Looking Information
This press release may include forward-looking information within the meaning of Canadian securities legislation, concerning the business of the Company. Forward-looking information is based on certain key expectations and assumptions made by the management of the Company. Although the Company believes that the expectations and assumptions on which such forward-looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because the Company can give no assurance that they will prove to be correct. Forward-looking statements contained in this press release are made as of the date of this press release. The Company disclaims any intent or obligation to update publicly any forward-looking information, whether as a result of new information, future events or results or otherwise, other than as required by applicable securities laws.
The CSE has not reviewed, approved or disapproved the content of this press release.
SOURCE CROP Infrastructure Corp.
Enzyme discovery could help in fight against TB
An enzyme structure discovery made by scientists at the University of Warwick could help to eradicate tuberculosis (TB)
Research by a team led by Dr Elizabeth Fullam, has revealed new findings about an enzyme found in Mycobacterium tuberculosis (Mtb) the bacterium that causes TB.
TB causes more deaths than any other infectious disease, including from HIV and malaria. In 2016 there were 10.4 million new cases of TB and 1.7 million people died. The rise in cases of TB that are resistant to the current therapies that are available means that there is an urgent need to develop new TB therapeutics.
Mtb is a highly unique bacterium and is enclosed within a distinctive cell wall that is comprised of unusual sugars and lipids which protect the bacteria from the host environment. Disruption of essential pathways involved in the assembly of the Mtb cell wall is an attractive approach for new TB drugs.
The team found a key structural motif in the tuberculosis N-acetylglucosamine-6-phosphate deacetylase (NagA) enzyme. Attacking this structural motif through the design and exploitation of new molecules will enable scientists to inhibit this critical pathway and kill TB.
Using the X-ray facilities at the Diamond Light Source, Harwell, they were provided with detailed molecular insights into how the NagA enzyme generates important precursors that are involved in Mtb cell wall biosynthesis and metabolism.
Dr Fullam, who is a Sir Henry Dale Fellow at the University of Warwick’s School of Life Sciences, said: “Tuberculosis is a major global health problem and the current drugs that we use today are over 40 years old. It is therefore vital that we discover new therapeutic agents to combat TB. In our studies, we have investigated the role of an enzyme in Mtb called NagA. This enzyme is a promising drug target as it is at a crucial metabolic chokepoint in Mtb. This means that a molecule that stops the enzyme from working would be an effective strategy for a drug and therefore it is critical to understand its function.
“Our group has identified a weak point within this protein that we can target and will now enable us to design specific molecules to block its function”
Using a range of biochemical and biophysical checks to determine the substrate specificity for the Mtb NagA enzyme they found a unique structural feauture in the Mtb NagA enzyme.This has revealed a molecular image of the protein and provides a platform to allow scientists to design new drugs that will hopefully inhibit this vital pathway and kill TB.
The research ‘Structural and functional determination of homologs of the Mycobacterium tuberculosis N-acetylglucosamine-6-phosphate deacetylase (NagA)’ is published in the Journal of Biological Chemistry
ENDS
For more information contact Nicola Jones, Media Relations Manager, University of Warwick N.Jones.1@warwick.ac.uk or 07920531221
Photo caption1 NagA protein crystals
Notes to Editors
Structural and functional determination of homologs of the Mycobacterium tuberculosis N-acetylglucosamine-6-phosphate deacetylase (NagA)’ is published in the Journal of Biological Chemistry
DOI.1074/jbc.RA118.002597
Authors
Mohd Syed Ahangar, School of Life Sciences, University of Warwick, Warwick, Coventry CV4 7AL, United Kingdom
Christopher M. Furze, School of Life Sciences, University of Warwick, Warwick, Coventry CV4 7AL, United Kingdom
Collette S. Guy, School of Life Sciences, University of Warwick, Warwick, Coventry CV4 7AL, United Kingdom; Department of Chemistry, University of Warwick, Warwick, Coventry CV4 7AL, United Kingdom
Charlotte Cooper, School of Life Sciences, University of Warwick, Warwick, Coventry CV4 7AL, United Kingdom
Kathryn S. Maskew, School of Life Sciences, University of Warwick, Warwick, Coventry CV4 7AL, United Kingdom
Ben Graham, Department of Chemistry, University of Warwick, Warwick, Coventry CV4 7AL, United Kingdom
Alexander D. Cameron, School of Life Sciences
Elizabeth Fullam, School of Life Sciences, University of Warwick, Warwick, Coventry CV4 7AL, United Kingdom
Funding
This work was supported by a Sir Henry Dale Fellowship (to E. F.) jointly funded by the Wellcome Trust and Royal Society Grant 104193/Z/14/Z, Wellcome Trust Grant 201442/Z/16/Z (to E. F.), Royal Society Research Grant RG120405 (to E. F.), and Wellcome Warwick Quantitative Biomedicine Programme Institution Strategic Support Fund Seed Grant 105627/Z/14/Z; a Midlands Doctoral Training Partnership Studentship BB/M01116X/ 1 (to C. C.); this work was also supported in part by Warwick Integrative Synthetic Biology research technology platform (Grant BB/M017982/1)
Ultimate Wimbledon Inspired Tennis Holidays & Tips for 2018
With Wimbledon 2018 well and truly under way, the ever-growing fever is tangible, and nobody is immune. Luckily, Health and Fitness Travel, the wellness holiday specialists, has the tried and tested cure, sharing their top tennis training holidays and tips from experts that are guaranteed to inspire you. Whether you’re as serious as Andy Murray or simply enjoy working up a sweat before the spa, gain the advantage this summer with an epic sporting holiday. After a morning on the court with expert coaches, ward off tennis elbow through the expertise of professional chiropractors and rejuvenating spa treatments, leaving your body ready to hit the courts again tomorrow. Game, set, match.
Top Tennis Holidays
Portugal: Annabel Croft Tennis at Pine Cliffs Resort
With a philosophy of ‘movement and repetition’, take your tennis to new heights on this one-week tennis coaching retreat developed by former British No.1, Annabel Croft. Whether you are a skilled tennis player or just starting to consider the sport, enjoy a secluded break, while experiencing the pleasures of learning and improving yourself at the Annabel Croft tennis academy. Facilities boast six high quality tennis courts and qualified trainers who run training and coaching sessions. The tennis programme includes highly paced drills and exercises to enjoy the training while growing in skill yourself.
Health and Fitness Travel (0203 397 8891 healthandfitnesstravel.com) offers 7 nights at Pine Cliffs from £1,840pp or £2,665 for single occupancy. Price includes accommodation, daily breakfast, 5 x group tennis lessons and return private transfers.
Cyprus: Tennis at Aphrodite Hills
Do you fancy yourself as the next Serena Williams or Roger Federer? The Tennis Academy at Aphrodite Hills in Cyprus is the perfect place for tennis enthusiasts of every age to achieve all their sporting goals. Whether you are a beginner or intermediate, the dedicated tennis coaches will help you improve your game and serving skills, that you can later show off in an invigorating match with other dedicated guests. After powering yourself out on the high-quality courts, unwind and soothe your muscles by paying the Retreat spa a visit to enjoy a hot stone, Swedish or therapeutic massage to make you feel relaxed and restored.
Health and Fitness Travel (0203 397 8891 healthandfitnesstravel.com) offers 7 nights at Aphrodite Hills from £1,180pp or £1,665 for single occupancy. Price includes accommodation, daily breakfast, 14 hours of coaching and return private transfers.
Spain: Marbella Club Tennis
Located just a ball toss away from the luxurious Mediterranean hideaway that is Marbella Club, follow in the footsteps of tennis greats like Serena Williams and Boris Becker at Puente Romano Tennis Club. With ten well-equipped courts and a talented team of professional coaches waiting to ‘serve’ you, there’s no better place to perfect your tennis technique. Unleash your competitive side with twice-weekly group tennis tournaments and channel your inner-champion as you put your new-found skills to the test. After a day of serve-and-volley, wind down with a personalised massage and relax in the beachfront Thalasso Spa with breath-taking views across the Med.
Health and Fitness Travel (0203 397 8891 healthandfitnesstravel.com) offers 7 nights at Marbella Club from £2,740pp or £4,940 for single occupancy. Price includes accommodation, daily breakfast, 6 x private tennis lessons and return private transfers.
Thailand: Thanyapura Tennis
Serve it and smash it with the guidance of professional mentors on this tennis holiday at Thanyapura, sheltered beneath the peaceful mountains of Phuket. Train amongst tennis stars and international teams on 6 competition-class courts. Compliment your tennis with a selection of fitness classes including spinning, Kinesis and Pilates. Reap the benefits of a rejuvenating sports massage at the resort spa or indulge in the experience with holistic treatments for an enhanced sense of well-being. Reconnect with your mind, body and soul at this dedicated fitness retreat and return home with a sharper game that will have your opponent’s running in circles.
Health and Fitness Travel (0203 397 8891 healthandfitnesstravel.com) offers 7 nights at Thanyapura from £600pp or £750 for single occupancy. Price includes accommodation, full board, 6x private tennis lessons and return private transfers.
St Lucia: BodyHoliday Tennis
Gain the advantage over your tennis game and your fitness levels on this active tennis holiday at BodyHoliday in St Lucia. Set upon the secluded bay of Cariblue, hit the courts for private coaching and group tennis lessons, before testing what you’ve learnt with a tennis competition between fellow guests. Round out your all-inclusive tennis holiday with a wide range of group fitness classes, land and water sports, including, yoga, Box Fit, mountain biking and kayaking. After an active day, relax at the luxury spa with a choice of daily treatments, including massages, body scrubs and facials.
Health and Fitness Travel (0203 397 8891 healthandfitnesstravel.com) offers 7 nights at BodyHoliday from £1,480pp or £1,580 for single occupancy. Price includes accommodation, all inclusive, 8x tennis lessons and return private transfers.
Antigua: Carlisle Bay Tennis
Add some Vitamin-D to your game as you soak up the sun training in the tropics at Carlisle Bay in the Caribbean. Beneath tropical palm trees, nine courts are a stone’s throw away from the turquoise waters edge, including four floodlit courts for cooler evening games. With six private tennis lessons included and optional complimentary clinics, you will have plenty of opportunity to improve your technique under the tuition of professional instructors. In-between games explore on a rainforest hike or take to the tropical waters paddle boarding, before rejuvenating with a deep tissue massage at the award-winning Blue Spa.
Health and Fitness Travel (0203 397 8891 healthandfitnesstravel.com) offers 7 nights at Carlisle Bay from £(please enquire). Price includes accommodation, breakfast, 6x private tennis lessons and return private transfers.
Top Tennis Tips from the Pros
- Learn a backhanded backspin
“The backhanded backspin is an indispensable move found in the repertoire of all good tennis players. This shot allows you to defend yourself against powerful punches, attack at the right moment and change the inertia of the game to keep your opponent off balance.
For this, you have to be able to hit the ball well and generate a good swing that does not make it lob too much, nor lose the force necessary to keep your opponent from counter-attacking during the game.”
Ramon Campuzano Rojas, Director of Puente Romano Tennis & Fitness Club, Marbella
- Fancy footwork
Footwork is a key aspect to success in tennis and how you move on the court is arguably the most important part of the game; a lack of proper footwork makes it nearly impossible to advance to a higher level in the sport. Even if you are lacking in speed, you can still be quick and effective on the court given the correct footwork, not only reaching tough balls, but also getting in an optimal position to hit the best possible shot. Follow these tips to polish up your footwork on the court:
Ready Position
Before you start approaching the ball, players should always begin in the “ready position” with knees and hips bent, legs shoulder width apart and weight equally distributed on both toes. This position allows you to move easily in any direction and should be used when anticipating the opponent’s next shot.
Split Step
Once your opponent contacts the ball you should perform a “split step” which consists of a small hop from the ready position towards the direction of the ball. This step will prepare you for your shot and allow for a quicker and more explosive movement to the ball.
Effective Movement
Quick, light, short steps are key to reaching the ball early, since these precise movements are what allow you to get in an ideal position for a good shot. Always stay on your toes and avoid taking long, heavy strides to reach the ball.
Timo Sivapruksa, Head Tennis Coach at Thanyapura Phuket, Thailand
- How to instantly raise your game
“It’s important to understand the best area to contact the ball. If the ball is too far away, you lose control and balance; if it's too close, you can't swing correctly. Getting the correct place to contact the ball will enable you to hit through the ball better.
Also choosing a suitable racket can make a huge difference; the main thing is to get a decent set of strings with good tension.”
Pat Cash, Wimbledon champion 1987
For advice, guidance and booking visit www.healthandfitnesstravel.com or call 0203 397 8891
